KLF5 and prostate cancer: In soft agar assays, the growth of AR-positive prostate cancer cells overexpressing KLF5 was suppressed by androgen withdrawal or enzalutamide treatment (Fig. 4b, e), and cell cycle activity was lowest in LTL-331 tumors when KLF5 expression and basal cell activity were highest (Fig. 5g–i).